

PatientID: HIVDR-774-23

Sebuttemba 27, 2023

### Color Code

■ HR: High-Level Resistance    ■ PLR: Potential Low-Level Resistance  
■ LR: Low-Level Resistance    ■ IR: Intermediate Resistance  
■ S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	HR	M46I;I54L;N88S;F53L
	DRV	LR	
	FPV	HR	
	IDV	IR	
	LPV	IR	
	NFV	HR	
	SQV	IR	
	TPV	S	
NRTI	ABC	IR	M41L;M184V;T215F;V75M
	AZT	HR	
	D4T	HR	
	DDI	HR	
	FTC	HR	
	LMV	HR	
	TDF	LR	
	DOR	LR	A98G
NNRTI	EFV	LR	
	ETR	PLR	
	NVP	IR	
	RPV	LR	
INSTI	BIC	S	
	CAB	S	
	DTG	S	
	EVG	S	
	RAL	S	

## Appendix

### Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
<b>PI</b>	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
	IDV	Indinavir
	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
<b>NRTI</b>	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
<b>NNRTI</b>	DOR	Doravirine
	EFV	Efavirenz
	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
<b>INSTI</b>	BIC	Bictegravir
	CAB	Cabotegravir
	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

### Comments

DRUG.CLASS	COMMENTS
<b>PI</b>	F53L is a nonpolymorphic accessory mutation selected primarily by SQV, IDV, ATV and LPV. In combination with other mutations, It is associated with reduced susceptibility to ATV and possibly LPV. F53Y is an uncommon nonpolymorphic accessory PI-selected mutation that has not been well studied.
	I54M/L are non-polymorphic mutations selected primarily by FPV and DRV. I54M/L reduce susceptibility to LPV, ATV, and DRV.
	M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV.
	N88S is a non-polymorphic mutation usually selected by NFV, ATV, and IDV. It confers high-level resistance to ATV and increases susceptibility to DRV.
	M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

<b>NRTI</b>	M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.
	T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.
	V75T/M/A/S are nonpolymorphic accessory NRTI-selected mutations. They appear to have minimal phenotypic effects on AZT, ABC, and TDF.
<b>NNRTI</b>	A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.
<b>INSTI</b>	